PharmaTelevision - Biota: Success With a Solid Product Pipeline

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Biota: Success With a Solid Product Pipeline

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Leigh Farrell, Vice President of Business Development at Biota.

Filmed at AusBiotech 2009, they discuss:

• Biota's recent financial successes
• the maturing of the company's pipeline in viral and respiratory disease
• key developments for Biota's programmes in 2009
• focusing on development
• Biota's share value and the reasons for its dramatic rise
• the company's future pipeline

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Biota's recent financial successes.

Fintan Walton:

Hello and welcome to PharmaTelevision News review here in Melbourne, Australia. On this show I have Leigh Farrell, who is the Vice President of Business Development at Biota based here in Melbourne. Welcome to the show.

Leigh Farrell:

Thanks Fintan Walton.

Fintan Walton:

Biota is one of these biotech companies that has been around the longest probably in Australia?

Leigh Farrell:

Since '87.

Fintan Walton:

And, indeed. And so it's a company that's maturing what's happen to Biota in the last few years it's been a tough year for biotech companies, is it been tough for Biota?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Leigh Farrell

Vice President, Business Development

Dr Leigh Farrell was appointed Vice President, Business Development on 24 April 2006. Prior to joining Biota, Dr Farrell spent approximately 4 years as an Associate Director at GBS Ventures Partners Limited, a specialist Life Sciences Venture Capital Fund. Dr Leigh Farrell previously held the positions of Research Manager at Johnson & Johnson Research Pty Ltd and Chief Executive Officer of Gene Shears Pty Limited. Dr Leigh Farrell has extensive international experience in corporate finance, business development, licensing, relationship management and intellectual property portfolio management in the biotechnology and pharmaceutical industries. He is currently the Chairman of the Competitive Business Environment Working Group established under the 2007 Biotechnology Strategic Development Plan for Victoria.

Biota

Biota is a leading anti-infective drug development company, based in Melbourne, Australia and Oxford, UK. Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza. Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defense against possible pandemic outbreaks of influenza.